Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1 2Phase 1/2 1

Status

Active not recruiting 2

Sponsor Class

NIH 2

Study Type

Interventional 2

Sponsor

Cancer Type

Thoracic 2Gastrointestinal 1Endocrine 1

Conditions

Neoplasm Metastasis 33Leukemia, Myeloid, Acute 24Melanoma 14Colorectal Neoplasms 14Breast Neoplasms 14Multiple Myeloma 13Myelodysplastic Syndromes 12Leukemia, Lymphocytic, Chronic, B-Cell 12Pancreatic Neoplasms 10Lymphoma, Follicular 10Prostatic Neoplasms 9Precursor Cell Lymphoblastic Leukemia-Lymphoma 9Lymphoma, Large B-Cell, Diffuse 8Triple Negative Breast Neoplasms 7Lymphoma, Non-Hodgkin 7Lymphoma, Mantle-Cell 7Lung Neoplasms 7Burkitt Lymphoma 7Ovarian Neoplasms 6Lymphoma, B-Cell, Marginal Zone 6Stomach Neoplasms 5Sarcoma 5Lymphoma, T-Cell, Cutaneous 5Lymphoma, T-Cell 5Lymphoma, B-Cell 5Lymphoma 5Leukemia, Biphenotypic, Acute 5Carcinoma, Renal Cell 5Carcinoma, Non-Small-Cell Lung 5Unspecified Adult Solid Tumor, Protocol Specific 4

Interventions

Cisplatin 21Etoposide 20Carboplatin 20Topotecan 13pembrolizumab 12durvalumab 11Paclitaxel 10Irinotecan 9Nivolumab 7Gemcitabine 7tremelimumab 6atezolizumab 6Radiotherapy 6Docetaxel 6Pemetrexed 5Ipilimumab 5Cyclophosphamide 5rovalpituzumab tesirine 4budigalimab 4Specimen Handling 4Injections 4Doxorubicin 4Bortezomib 4130-nm albumin-bound paclitaxel 4venetoclax 3talazoparib 3olaparib 3fludarabine 3etoposide phosphate 3Platinum 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1 × Small Cell Lung Carcinoma × Biopsy × Clear all
NCT04514497 2026-06-02

Testing the Addition of an Anti-cancer Drug, BAY 1895344, to Usual Chemotherapy for Advanced Stage Solid Tumors, With a Specific Focus on Patients With Small Cell Lung Cancer, Poorly Differentiated Neuroendocrine Cancer, and Pancreatic Cancer

National Cancer Institute (NCI)

Phase 1 Active not recruiting
29 enrolled 25 charts
EndocrineGastrointestinalThoracic

Lung Neoplasms, Neoplasm Metastasis, Pancreatic Neoplasms, Carcinoma, Neuroendocrine, Small Cell Lung Carcinoma

NCT05353439 2026-05-13

Testing of Tazemetostat in Combination With Topotecan and Pembrolizumab in Patients With Recurrent Small Cell Lung Cancer

National Cancer Institute (NCI)

Phase 1 Active not recruiting
18 enrolled
Thoracic

Small Cell Lung Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡